BIIBBIIB
US • —
$216.06
P/E
23.19
PEG
—
FCF Yield
—
Rev Growth YoY
+1.2% YoY
Gross Margin
75.5%
Health Score
8/10
D/E Ratio
0.34
Confidence
MEDIUM
Business Snapshot
Biogen focuses on discovering and developing therapies for neurological diseases, with a core franchise in multiple sclerosis treatments and recent expansion into Alzheimer's disease with Aduhelm and Leqembi. The company operates in the highly regulated biopharmaceutical sector where it holds a strong competitive position, particularly in MS, though it faces increasing competition from generics and next-generation therapies. Revenue growth remains modest at 1.2% year-over-year, reflecting a mature MS portfolio and ongoing commercial uncertainty for its newer Alzheimer's franchise. A defining characteristic of Biogen is its heavy reliance on its legacy MS revenue stream while attempting to pivot into the high-risk, high-reward Alzheimer's market, which requires significant ongoing R&D investment.
Financial Health
Gross margin is strong at 75.5%, while net margin stands at 13.8%, indicating decent profitability after operating expenses, though net margin compression has followed earnings declines. The balance sheet is conservative with a debt-to-equity ratio of just 0.34x and a current ratio of 2.68x, providing ample liquidity and financial flexibility for both R&D investment and shareholder returns...
Risk Assessment
- EARNINGS QUALITY — Earnings declined 8.1% year-over-year, even as revenue grew 1.2%, indicating margin compression that may signal operational inefficiency or increased cost pressures.
- REVENUE DECELERATION — Revenue growth of only 1.2% YoY reflects a mature product portfolio with minimal top-line expansion, leaving the stock reliant on pipeline catalysts for meaningful growth.
- TECHNICALS — RSI, MACD, and moving average data unavailable for this period; momentum cannot be independently confirmed.
- VALUATION DIVERGENCE — Both FMP DCF fair value and the Python-based DCF estimate are unavailable, meaning no intrinsic value anchor exists to assess whether the current price represents a discount or premium....
Gross margin is strong at 75.5%, while net margin stands at 13.8%, indicating decent profitability after operating expenses, though net margin compression has followed earnings declines. The balance sheet is conservative with a debt-to-equity ratio of just 0.34x and a current ratio of 2.68x, providing ample liquidity and financial flexibility for both R&D investment and shareholder returns. Free cash flow data is not available, which limits a full assessment of cash generation capability and capital allocation discipline. Overall, the company exhibits solid profitability and a fortress-like balance sheet with low leverage, supporting its ability to fund operations and return capital to shareholders without dilution risk.
- EARNINGS QUALITY — Earnings declined 8.1% year-over-year, even as revenue grew 1.2%, indicating margin compression that may signal operational inefficiency or increased cost pressures. - REVENUE DECELERATION — Revenue growth of only 1.2% YoY reflects a mature product portfolio with minimal top-line expansion, leaving the stock reliant on pipeline catalysts for meaningful growth. - TECHNICALS — RSI, MACD, and moving average data unavailable for this period; momentum cannot be independently confirmed. - VALUATION DIVERGENCE — Both FMP DCF fair value and the Python-based DCF estimate are unavailable, meaning no intrinsic value anchor exists to assess whether the current price represents a discount or premium.
Unlock the full AI report
Full 8-section analysis includes:
Metric deep-dives